Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [912]
News [3692]
Articles [22]
Editorials [1]
Conferences [136]
elearning [0]
Osimertinib adjuvant therapy in patients with early stage EGFR mutated NSCLC...
Dr Masahito Tsuboi - National Cancer Center Hospital, Tokyo, Japan
Osimertinib adjuvant therapy in patients with early stage EGFR mutated NSCLC after tumour resection ( Dr Masahito Tsuboi - National Cancer Center Hospital, Tokyo, Japan )
22 Sep 2020
OncoAlert and ecancer weekly roundup for August 24-29 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly roundup for August 24-29 2020 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
1 Sep 2020
OncoAlert and ecancer weekly roundup for August 17-23 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly roundup for August 17-23 2020 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
24 Aug 2020
Atezolizumab as monotherapy or in combination with cobimetinib in biliary tract...
Dr Mark Yarchoan - John Hopkins Medicine, Baltimore, USA
Atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers ( Dr Mark Yarchoan - John Hopkins Medicine, Baltimore, USA )
30 Jul 2020
The impact of COVID-19 on ALL patients in Spain
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
The impact of COVID-19 on ALL patients in Spain ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )
22 Jul 2020
CheckMate 459: Long-term survival outcomes with nivolumab versus sorafenib as...
Prof Bruno Sangro - University of Navarra, Pamplona, Spain
CheckMate 459: Long-term survival outcomes with nivolumab versus sorafenib as first-line treatment in aHCC ( Prof Bruno Sangro - University of Navarra, Pamplona, Spain )
15 Jul 2020
Background of the KEYNOTE-158 trial for pembrolizumab in advanced mesothelioma
Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA
Background of the KEYNOTE-158 trial for pembrolizumab in advanced mesothelioma ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )
15 Jul 2020
Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with...
Dr Haneen Shalabi - National Cancer Institute, NIH, Bethesda, USA
Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL ( Dr Haneen Shalabi - National Cancer Institute, NIH, Bethesda, USA )
30 Jun 2020
New CAR T therapy for relapsed and refractory ALL
Dr Claire Roddie - University College London, London, UK
New CAR T therapy for relapsed and refractory ALL ( Dr Claire Roddie - University College London, London, UK )
25 Jun 2020
Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma
Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA
Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma ( Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA )
16 Jun 2020
Regulating haematopoietic stem cell dormancy and ageing through the netrin-1...
Dr Simon Renders - German Cancer Research Center (DKFZ), Heidelberg, Germany
Regulating haematopoietic stem cell dormancy and ageing through the netrin-1-neogenin axis ( Dr Simon Renders - German Cancer Research Center (DKFZ), Heidelberg, Germany )
13 Jun 2020
CTC count as a prognostic marker for androgen deprivation plus orteronel or...
Dr Amir Goldkorn - Keck School of Medicine of USC, Los Angeles, USA
CTC count as a prognostic marker for androgen deprivation plus orteronel or bicalutamide in mCSPC ( Dr Amir Goldkorn - Keck School of Medicine of USC, Los Angeles, USA )
12 Jun 2020

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation